Condition: Treatment Resistant Depression · Sponsor: COMPASS Pathways
Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Lighthouse Psychiatry Scottsdale | Gilbert, Arizona, United States | — |
| Clinical Innovations, Inc. | Bellflower, California, United States | — |
| M3 Wake Research | Encino, California, United States | — |
| The Regents of the University of California - San Diego | La Jolla, California, United States | — |
| Kadima Neuropsychiatry Institute | La Jolla, California, United States | — |
| CalNeuro Research Group, Inc | Los Angeles, California, United States | — |
| Catalina Research Institute, LLC | Montclair, California, United States | — |
| Piedmont Hospital Neuroscience Centre | Oakland, California, United States | — |
| ATP Clinical Research, Inc. | Orange, California, United States | — |
| CITrials | Riverside, California, United States | — |
| Lumos Clinical Research Center | San Jose, California, United States | — |
| Syrentis Clinical Research | Santa Ana, California, United States | — |
+ 104 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.